NCT00055562
Completed
Phase 2
Multicenter, Randomized, Controlled, Double-Blind, Parallel-Group Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2 or IFN Based Therapy
DrugsCC 5013
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Melanoma
- Sponsor
- Celgene Corporation
- Enrollment
- 274
- Locations
- 31
- Status
- Completed
- Last Updated
- 20 years ago
Overview
Brief Summary
Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects will be treated in repeating 4 week cycles.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (31)
Loading locations...
Similar Trials
Completed
Phase 3
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.MelanomaNeoplasm MetastasisNCT00057616Celgene274
Completed
Phase 3
Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter PolymorphismsAlcohol Use DisorderNCT04101227Adial Pharmaceuticals302
Completed
Phase 3
An Study of Efficacy and Safety of ClevudineChronic Hepatitis BNCT01192854Eisai Co., Ltd.288
Unknown
Not Applicable
Effect of a Mixture of Fibers and Carbohydrates on Intestinal Transit in Children Diagnosed With Functional ConstipationConstipation - FunctionalNCT04028258Laboratorios Ordesa120
Active, not recruiting
Phase 3
A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic CancerStage III Pancreatic CancerNCT03899636Angiodynamics, Inc.528